WO2004007536A3 - Nouvelles interactions de la proteine du virus d'epstein-barr ebna1, compositions et methodes associees - Google Patents

Nouvelles interactions de la proteine du virus d'epstein-barr ebna1, compositions et methodes associees Download PDF

Info

Publication number
WO2004007536A3
WO2004007536A3 PCT/CA2003/001019 CA0301019W WO2004007536A3 WO 2004007536 A3 WO2004007536 A3 WO 2004007536A3 CA 0301019 W CA0301019 W CA 0301019W WO 2004007536 A3 WO2004007536 A3 WO 2004007536A3
Authority
WO
WIPO (PCT)
Prior art keywords
ebna1
complexes
methods
polypeptide
epstein
Prior art date
Application number
PCT/CA2003/001019
Other languages
English (en)
Other versions
WO2004007536A2 (fr
Inventor
Lori Frappier
Melissa Holowaty
Jack Greenblatt
Mahel Zeghouf
Original Assignee
Affinium Pharm Inc
Lori Frappier
Melissa Holowaty
Jack Greenblatt
Mahel Zeghouf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affinium Pharm Inc, Lori Frappier, Melissa Holowaty, Jack Greenblatt, Mahel Zeghouf filed Critical Affinium Pharm Inc
Priority to AU2003246485A priority Critical patent/AU2003246485A1/en
Publication of WO2004007536A2 publication Critical patent/WO2004007536A2/fr
Publication of WO2004007536A3 publication Critical patent/WO2004007536A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/705—Fusion polypeptide containing domain for protein-protein interaction containing a protein-A fusion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des complexes composés d'EBNA1 et d'au moins un polypeptide des complexes d'EBNA1, ainsi que des méthodes d'utilisation associées. On utilise des complexes d'EBNA1 purifiés et des polypeptides des complexes d'EBNA1, ainsi que des variantes des complexes d'EBNA1 telles que des complexes de fragments polypeptidiques ou de fusions polypeptidiques, ainsi que des molécules chimères comprenant des composants polypeptidiques des complexes d'EBNA1. Cette invention concerne également des méthodes de préparation de ces complexes d'EBNA1 et des polypeptides des complexes d'EBNA1, des méthodes de détection, d'identification et de purification des complexes d'EBNA1, des méthodes d'identification de composés qui modulent les complexes d'EBNA1 et les polypeptides des complexes d'EBNA1 ainsi que des méthodes de traitement ou de diagnostic de troubles induits par le virus d'Epstein-Barr utilisant les complexes d'EBNA1 et les polypeptides des complexes d'EBNA1 ainsi que des composants qui les modulent.
PCT/CA2003/001019 2002-07-16 2003-07-16 Nouvelles interactions de la proteine du virus d'epstein-barr ebna1, compositions et methodes associees WO2004007536A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003246485A AU2003246485A1 (en) 2002-07-16 2003-07-16 Interactions of the epstein-barr virus protein ebna1, and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39611802P 2002-07-16 2002-07-16
US60/396,118 2002-07-16

Publications (2)

Publication Number Publication Date
WO2004007536A2 WO2004007536A2 (fr) 2004-01-22
WO2004007536A3 true WO2004007536A3 (fr) 2004-05-06

Family

ID=30115975

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2003/001019 WO2004007536A2 (fr) 2002-07-16 2003-07-16 Nouvelles interactions de la proteine du virus d'epstein-barr ebna1, compositions et methodes associees

Country Status (2)

Country Link
AU (1) AU2003246485A1 (fr)
WO (1) WO2004007536A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2881746B1 (fr) * 2005-02-07 2007-04-13 Centre Nat Rech Scient Epitopes t cd4+des antigenes de latence de type i et ii du virus epstein-barr aptes a etre reconnus par la majorite des individus de la population caucasienne et leurs applications
US8551774B2 (en) * 2005-03-17 2013-10-08 National Research Council Of Canada Expression vectors containing a truncated epstein barr nuclear antigen 1 lacking the Gly-Gly-Ala domain for enhanced transient gene expression
CN108061798B (zh) * 2016-11-07 2019-11-08 国药中生生物技术研究院有限公司 检测HBsAg/anti-HBs复合物体系中有效成分的量的方法和应用
WO2024022466A1 (fr) * 2022-07-29 2024-02-01 Wuxi Biologics (Shanghai) Co., Ltd. Ebna1 modifié à fonction améliorée pour l'expression de protéines dans des cellules de mammifère

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994006912A1 (fr) * 1992-09-14 1994-03-31 Akzo Nobel N.V. Peptides du virus d'epstein-barr et anticorps diriges contre ces peptides
US20010049093A1 (en) * 1997-11-12 2001-12-06 Sugden William M. Inhibition of viral gene activities

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994006912A1 (fr) * 1992-09-14 1994-03-31 Akzo Nobel N.V. Peptides du virus d'epstein-barr et anticorps diriges contre ces peptides
US20010049093A1 (en) * 1997-11-12 2001-12-06 Sugden William M. Inhibition of viral gene activities

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DANTUMA N P ET AL: "AVOIDING PROTEASOMAL PROCESSING: THE CASE OF EBNA1", CURRENT TOPICS IN MICROBIOLOGY AND IMMUNOLOGY, SPRINGER, BERLIN,, DE, vol. 269, 2002, pages 23 - 36, XP008026278, ISSN: 0070-217X *
HOLOWATY MELISSA N ET AL: "Protein profiling with Epstein-Barr nuclear antigen-1 reveals an interaction with the herpesvirus-associated ubiquitin-specific protease HAUSP/USP7.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 278, no. 32, 3 June 2003 (2003-06-03), pages 29987 - 29994, XP002266783, ISSN: 0021-9258 *
ITO SAYURI ET AL: "Epstein-Barr virus nuclear antigen-1 binds to nuclear transporter karyopherin alpha1/NPI-1 in addition to karyopherin alpha2/Rch1", VIROLOGY, vol. 266, no. 1, 5 January 2000 (2000-01-05), pages 110 - 119, XP004436188, ISSN: 0042-6822 *
KAPOOR PRIYA ET AL: "Reconstitution of Epstein-Barr virus-based plasmid partitioning in budding yeast", EMBO (EUROPEAN MOLECULAR BIOLOGY ORGANIZATION) JOURNAL, vol. 20, no. 1-2, 15 January 2001 (2001-01-15), pages 222 - 230, XP002266782, ISSN: 0261-4189 *
KLIM ARIANNA L ET AL: "An imperfect correlation between DNA replication activity of Epstein-Barr virus nuclear antigen 1 (EBNA1) and binding to the nuclear import receptor, rch1/importin alpha", VIROLOGY, vol. 239, no. 2, 22 December 1997 (1997-12-22), pages 340 - 351, XP004452374, ISSN: 0042-6822 *
WENDELBURG ET AL: "AN ENHANCED EBNA1 VARIANT WITH REDUCED IR3 DOMAIN FOR LONG-TERM EPISOMAL MAINTENANCE AND TRANSGENE EXPRESSION OF ORIP-BASED PLASMIDS IN HUMAN CELLS", GENE THERAPY, MACMILLAN PRESS LTD., BASINGSTOKE, GB, vol. 5, May 1998 (1998-05-01), pages 1389 - 1399, XP002931315, ISSN: 0969-7128 *

Also Published As

Publication number Publication date
AU2003246485A8 (en) 2004-02-02
AU2003246485A1 (en) 2004-02-02
WO2004007536A2 (fr) 2004-01-22

Similar Documents

Publication Publication Date Title
EP0832973A3 (fr) Protéine de liaison de GTP
NO2011003I2 (fr)
DE69534588D1 (de) Protocadherin-proteine und verwendungen davon
PT1214600E (pt) Determinacao de proteinas de ligacao a adrenomedulina
WO2004029072A3 (fr) Molecules interagissant avec prpsc et utilisations associees
WO2004048521A3 (fr) Composition et procede pour traiter la nephropathie lupique
DK0948604T3 (da) Screeningsmetoder for forbindelser som binder til PYK2-polypeptidet
WO2003087138A3 (fr) Procedes d'identification de facteurs polypeptidiques ayant une interaction avec l'arn
WO2004099388A3 (fr) Complexes de polypeptides cbl-b et methodes associees
WO2000053742A3 (fr) Polynucleotides et proteines codees par ceux-ci
MXPA03006218A (es) Receptor de citosina tipo 2 y acidos nucleicos que codifican para lo mismo.
WO2002012279A3 (fr) Gene et proteine relatifs a la schizophrenie
WO2004007536A3 (fr) Nouvelles interactions de la proteine du virus d'epstein-barr ebna1, compositions et methodes associees
WO2003068940A3 (fr) Complexes et procedes d'utilisation correspondants
WO2004090103A8 (fr) Identification de nouveaux nogo-recepteurs et procedes associes
WO2002092765A3 (fr) Nouveaux inhibiteurs de la telomerase et utilisations correspondantes
WO2001029220A3 (fr) Peptides antigeniques mage-a12 et utilisation
EP0897011A3 (fr) Arginine deiminase
WO2001074903A3 (fr) Molecules du type recepteur de cd20/ige et leurs applications
WO2003025147A3 (fr) Nouveaux polynucleotides et proteines codees par ceux-ci
EP0911409A3 (fr) Deformylase
WO2000070046A3 (fr) Nouveaux polypeptides et polynucleotides les codant
EP0801132A3 (fr) Protéine FtsH des staphylocoques
AU2003261102A1 (en) Novel polynucleotide and polypeptide sequences and uses thereof
WO2003060067A3 (fr) Acides nucleiques et polypeptides p85-alpha, et procedes associes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP